Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014;64(2):83–103.
Article
PubMed
Google Scholar
Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003;3(3):203–16.
Article
CAS
PubMed
Google Scholar
Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children’s oncology group study. J Clin Oncol. 2009;27(7):1007–13.
Article
CAS
PubMed
PubMed Central
Google Scholar
Seeger RC, Reynolds CP, Gallego R, Stram DO, Gerbing RB, Matthay KK. Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children’s Cancer Group Study. J Clin Oncol. 2000;18(24):4067–76.
Article
CAS
PubMed
Google Scholar
Wilson JS, Gains JE, Moroz V, Wheatley K, Gaze MN. A systematic review of 131I-meta iodobenzylguanidine molecular radiotherapy for neuroblastoma. Eur J Cancer. 2014;50(4):801–15.
Article
CAS
PubMed
Google Scholar
Kushner BH. Neuroblastoma: a disease requiring a multitude of imaging studies. J Nucl Med. 2004;45(7):1172–88.
PubMed
Google Scholar
Howman-Giles R, Shaw PJ, Uren RF, Chung DK. Neuroblastoma and other neuroendocrine tumors. Semin Nucl Med. 2007;37(4):286–302.
Article
PubMed
Google Scholar
Reubi JC, Schaer JC, Waser B, Mengod G. Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res. 1994;54(13):3455–9.
CAS
PubMed
Google Scholar
Georgantzi K, Tsolakis AV, Stridsberg M, Jakobson A, Christofferson R, Janson ET. Differentiated expression of somatostatin receptor subtypes in experimental models and clinical neuroblastoma. Pediatr Blood Cancer. 2011;56(4):584–9.
Article
PubMed
Google Scholar
Alexander N, Marrano P, Thorner P, Naranjo A, Van Ryn C, Martinez D, et al. Prevalence and clinical correlations of somatostatin receptor-2 (SSTR2) expression in neuroblastoma. J Pediatr Hematol Oncol. 2019;41(3):222–7.
Article
CAS
PubMed
PubMed Central
Google Scholar
Moertel CL, Reubi JC, Scheithauer BS, Schaid DJ, Kvols LK. Expression of somatostatin receptors in childhood neuroblastoma. Am J Clin Pathol. 1994;102(6):752–6.
Article
CAS
PubMed
Google Scholar
Albers AR, O’Dorisio MS, Balster DA, Caprara M, Gosh P, Chen F, et al. Somatostatin receptor gene expression in neuroblastoma. Regul Pept. 2000;88(1–3):61–73.
Article
CAS
PubMed
Google Scholar
Pauwels E, Cleeren F, Bormans G, Deroose CM. Somatostatin receptor PET ligands—the next generation for clinical practice. Am J Nucl Med Mol Imaging. 2018;8(5):311–31.
CAS
PubMed
PubMed Central
Google Scholar
Fani M, Nicolas GP, Wild D. Somatostatin receptor antagonists for imaging and therapy. J Nucl Med. 2017;58(Suppl 2):61S-S66.
Article
CAS
PubMed
Google Scholar
Stueven AK, Kayser A, Wetz C, Amthauer H, Wree A, Tacke F, et al. Somatostatin analogues in the treatment of neuroendocrine tumors: past, present and future. Int J Mol Sci. 2019;20(12):3049.
Article
CAS
PubMed Central
Google Scholar
Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of (177)Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125–35.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kong G, Hofman MS, Murray WK, Wilson S, Wood P, Downie P, et al. Initial experience with gallium-68 DOTA-octreotate PET/CT and peptide receptor radionuclide therapy for pediatric patients with refractory metastatic neuroblastoma. J Pediatr Hematol Oncol. 2016;38(2):87–96.
Article
CAS
PubMed
Google Scholar
Gains JE, Bomanji JB, Fersht NL, Sullivan T, D’Souza D, Sullivan KP, et al. 177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma. J Nucl Med. 2011;52(7):1041–7.
Article
PubMed
Google Scholar
Gains JE, Moroz V, Aldridge MD, Wan S, Wheatley K, Laidler J, et al. A phase IIa trial of molecular radiotherapy with 177-lutetium DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma. Eur J Nucl Med Mol Imaging. 2020;47(10):2348–57.
Article
CAS
PubMed
Google Scholar
Alexander N, Vali R, Ahmadzadehfar H, Shammas A, Baruchel S. Review: The role of radiolabeled DOTA-conjugated peptides for imaging and treatment of childhood neuroblastoma. Curr Radiopharm. 2018;11(1):14–21.
Article
CAS
PubMed
Google Scholar
Johnbeck CB, Knigge U, Loft A, Berthelsen AK, Mortensen J, Oturai P, et al. Head-to-head comparison of (64)Cu-DOTATATE and (68)Ga-DOTATOC PET/CT: a prospective study of 59 patients with neuroendocrine tumors. J Nucl Med. 2017;58(3):451–7.
Article
CAS
PubMed
Google Scholar
Pfeifer A, Knigge U, Mortensen J, Oturai P, Berthelsen AK, Loft A, et al. Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study. J Nucl Med. 2012;53(8):1207–15.
Article
CAS
PubMed
Google Scholar
Bunka M, Muller C, Vermeulen C, Haller S, Turler A, Schibli R, et al. Imaging quality of (44)Sc in comparison with five other PET radionuclides using Derenzo phantoms and preclinical PET. Appl Radiat Isotop. 2016;110:129–33.
Article
CAS
Google Scholar
Maheshwari V, Dearling JLJ, Treves ST, Packard AB. Measurement of the rate of copper(II) exchange for 64Cu complexes of bifunctional chelators. Inorg Chim Acta. 2012;393:318–23.
Article
CAS
Google Scholar
Paterson BM, Roselt P, Denoyer D, Cullinane C, Binns D, Noonan W, et al. PET imaging of tumours with a 64Cu labeled macrobicyclic cage amine ligand tethered to Tyr3-octreotate. Dalton Trans. 2014;43(3):1386–96.
Article
CAS
PubMed
Google Scholar
Di Bartolo N, Sargeson AM, Smith SV. New 64Cu PET imaging agents for personalised medicine and drug development using the hexa-aza cage. SarAr Org Biomol Chem. 2006;4(17):3350–7.
Article
PubMed
CAS
Google Scholar
Hicks RJ, Jackson P, Kong G, Ware RE, Hofman MS, Pattison DA, et al. (64)Cu-SARTATE PET imaging of patients with neuroendocrine tumors demonstrates high tumor uptake and retention, potentially allowing prospective dosimetry for peptide receptor radionuclide therapy. J Nucl Med. 2019;60(6):777–85.
Article
CAS
PubMed
PubMed Central
Google Scholar
Cullinane C, Jeffery CM, Roselt PD, van Dam EM, Jackson S, Kuan K, et al. Peptide receptor radionuclide therapy with (67)Cu-CuSarTATE is highly efficacious against a somatostatin positive neuroendocrine tumor model. J Nucl Med. 2020;61:1800–5.
Article
CAS
PubMed
Google Scholar
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2020 August 18. Identifier NCT04023331, 67Cu-SARTATETM peptide receptor radionuclide therapy administered to pediatric patients with high-risk neuroblastoma. First posted 2019 July 17. Cited 2021 February 8. [about 1 screen]. https://www.clinicaltrials.gov/ct2/show/NCT04023331.
Kume M, Carey PC, Gaehle G, Madrid E, Voller T, Margenau W, et al. A semi-automated system for the routine production of copper-64. Appl Radiat Isotop. 2012;70(8):1803–6.
Article
CAS
Google Scholar
Tumilowicz JJ, Nichols WW, Cholon JJ, Greene AE. Definition of a continuous human cell line derived from neuroblastoma. Cancer Res. 1970;30(8):2110–8.
CAS
PubMed
Google Scholar
Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging. 2003;2(3):131–7.
Article
PubMed
Google Scholar
Mies G, Niebuhr I, Hossmann KA. Simultaneous measurement of blood flow and glucose metabolism by autoradiographic techniques. Stroke J Cereb Circ. 1981;12(5):581–8.
Article
CAS
Google Scholar
Weckbecker G, Tolcsvai L, Liu R, Bruns C. Preclinical studies on the anticancer activity of the somatostatin analogue octreotide (SMS 201-995). Metab Clin Exp. 1992;41(9 Suppl 2):99–103.
Article
CAS
PubMed
Google Scholar
Weckbecker G, Tolcsvai L, Liu R, Bruns C. Preclinical studies on the anticancer activity of the somatostatin analog octreotide (SMS 201-995). Digestion. 1993;54(Suppl 1):98–103.
Article
CAS
PubMed
Google Scholar
Ullrich M, Bergmann R, Peitzsch M, Zenker EF, Cartellieri M, Bachmann M, et al. Multimodal somatostatin receptor theranostics using [(64)Cu]Cu-/[(177)Lu]Lu-DOTA-(Tyr(3))octreotate and AN-238 in a mouse pheochromocytoma model. Theranostics. 2016;6(5):650–65.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zhang L, Vines DC, Scollard DA, McKee T, Komal T, Ganguly M, et al. Correlation of somatostatin receptor-2 expression with gallium-68-DOTA-TATE uptake in neuroblastoma xenograft models. Contrast Media Mol Imaging. 2017;2017:9481276.
PubMed
PubMed Central
Google Scholar
Schmitt A, Bernhardt P, Nilsson O, Ahlman H, Kolby L, Schmitt J, et al. Biodistribution and dosimetry of 177Lu-labeled [DOTA0, Tyr3]octreotate in male nude mice with human small cell lung cancer. Cancer Biother Radiopharm. 2003;18(4):593–9.
Article
CAS
PubMed
Google Scholar
Bison SM, Haeck JC, Bol K, Koelewijn SJ, Groen HC, Melis M, et al. Optimization of combined temozolomide and peptide receptor radionuclide therapy (PRRT) in mice after multimodality molecular imaging studies. EJNMMI Res. 2015;5(1):62.
Article
PubMed
PubMed Central
CAS
Google Scholar
Lewin J, Cullinane C, Akhurst T, Waldeck K, Watkins DN, Rao A, et al. Peptide receptor chemoradionuclide therapy in small cell carcinoma: from bench to bedside. Eur J Nucl Med Mol Imaging. 2015;42(1):25–32.
Article
CAS
PubMed
Google Scholar
Strosberg J, Kunz PL, Hendifar A, Yao J, Bushnell D, Kulke MH, et al. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with (177)Lu-Dotatate: an analysis of the NETTER-1 study. Eur J Nucl Med Mol Imaging. 2020;47:2372–82.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bernhardt P, Ahlman H, Forssell-Aronsson E. Model of metastatic growth valuable for radionuclide therapy. Med Phys. 2003;30(12):3227–32.
Article
CAS
PubMed
Google Scholar
Emmett L, Willowson K, Violet J, Shin J, Blanksby A, Lee J. Lutetium (177) PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. J Med Radiat Sci. 2017;64(1):52–60.
Article
PubMed
PubMed Central
Google Scholar